173 related articles for article (PubMed ID: 19378123)
1. Sendai virus for cancer immunotherapy.
Ueda Y; Hasegawa M; Yonemitsu Y
Methods Mol Biol; 2009; 515():299-308. PubMed ID: 19378123
[TBL] [Abstract][Full Text] [Related]
2. Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
Yoneyama Y; Ueda Y; Akutsu Y; Matsunaga A; Shimada H; Kato T; Kubota-Akizawa M; Okano S; Shibata S; Sueishi K; Hasegawa M; Ochiai T; Yonemitsu Y
Biochem Biophys Res Commun; 2007 Mar; 355(1):129-35. PubMed ID: 17292867
[TBL] [Abstract][Full Text] [Related]
3. Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus.
Komaru A; Ueda Y; Furuya A; Tanaka S; Yoshida K; Kato T; Kinoh H; Harada Y; Suzuki H; Inoue M; Hasegawa M; Ichikawa T; Yonemitsu Y
J Immunol; 2009 Oct; 183(7):4211-9. PubMed ID: 19734206
[TBL] [Abstract][Full Text] [Related]
4. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Kinoh H; Inoue M; Komaru A; Ueda Y; Hasegawa M; Yonemitsu Y
Gene Ther; 2009 Mar; 16(3):392-403. PubMed ID: 19037241
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
Yonemitsu Y; Ueda Y; Kinoh H; Hasegawa M
Front Biosci; 2008 Jan; 13():1892-8. PubMed ID: 17981677
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.
Yonemitsu Y; Ueda Y; Kinoh H; Hasegawa M
Front Biosci; 2008 May; 13():4953-9. PubMed ID: 18508560
[TBL] [Abstract][Full Text] [Related]
7. Comparison between Sendai virus and adenovirus vectors to transduce HIV-1 genes into human dendritic cells.
Hosoya N; Miura T; Kawana-Tachikawa A; Koibuchi T; Shioda T; Odawara T; Nakamura T; Kitamura Y; Kano M; Kato A; Hasegawa M; Nagai Y; Iwamoto A
J Med Virol; 2008 Mar; 80(3):373-82. PubMed ID: 18205221
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats.
Iwadate Y; Inoue M; Saegusa T; Tokusumi Y; Kinoh H; Hasegawa M; Tagawa M; Yamaura A; Shimada H
Clin Cancer Res; 2005 May; 11(10):3821-7. PubMed ID: 15897582
[TBL] [Abstract][Full Text] [Related]
9. Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene.
Tatsuta K; Tanaka S; Tajiri T; Shibata S; Komaru A; Ueda Y; Inoue M; Hasegawa M; Suita S; Sueishi K; Taguchi T; Yonemitsu Y
Gene Ther; 2009 Feb; 16(2):240-51. PubMed ID: 18987675
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.
Tosch C; Geist M; Ledoux C; Ziller-Remi C; Paul S; Erbs P; Corvaia N; Von Hoegen P; Balloul JM; Haegel H
Cancer Gene Ther; 2009 Apr; 16(4):310-9. PubMed ID: 18949016
[TBL] [Abstract][Full Text] [Related]
11. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene.
Shibata S; Okano S; Yonemitsu Y; Onimaru M; Sata S; Nagata-Takeshita H; Inoue M; Zhu T; Hasegawa M; Moroi Y; Furue M; Sueishi K
J Immunol; 2006 Sep; 177(6):3564-76. PubMed ID: 16951315
[TBL] [Abstract][Full Text] [Related]
12. Sendai virus for gene therapy and vaccination.
Griesenbach U; Inoue M; Hasegawa M; Alton EW
Curr Opin Mol Ther; 2005 Aug; 7(4):346-52. PubMed ID: 16121700
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
Moriya C; Horiba S; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Matano T
Biochem Biophys Res Commun; 2008 Jul; 371(4):850-4. PubMed ID: 18466766
[TBL] [Abstract][Full Text] [Related]
14. Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems.
Kaneda Y
Expert Opin Drug Deliv; 2008 Feb; 5(2):221-33. PubMed ID: 18248320
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
Sbiera S; Wortmann S; Fassnacht M
Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
[TBL] [Abstract][Full Text] [Related]
16. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy.
Meng J; Meng J; Duan J; Kong H; Li L; Wang C; Xie S; Chen S; Gu N; Xu H; Yang XD
Small; 2008 Sep; 4(9):1364-70. PubMed ID: 18720440
[TBL] [Abstract][Full Text] [Related]
17. Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.
Zimmermann M; Armeanu-Ebinger S; Bossow S; Lampe J; Smirnow I; Schenk A; Lange S; Weiss TS; Neubert W; Lauer UM; Bitzer M
PLoS One; 2014; 9(3):e90508. PubMed ID: 24598703
[TBL] [Abstract][Full Text] [Related]
18. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques.
Takeda A; Igarashi H; Kawada M; Tsukamoto T; Yamamoto H; Inoue M; Iida A; Shu T; Hasegawa M; Matano T
Vaccine; 2008 Dec; 26(52):6839-43. PubMed ID: 18930099
[TBL] [Abstract][Full Text] [Related]
20. New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
Kinoh H; Inoue M
Front Biosci; 2008 Jan; 13():2327-34. PubMed ID: 17981715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
